Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#81 / 200 Total
STOK - Stoke Therapeutics Inc - Stock Price Chart
TickerSTOK [NASD, RUT]
CompanyStoke Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap336.91MEPS (ttm)-1.68
P/E-EPS this Y27.74%
Forward P/E-EPS next Y-89.14%
PEG-EPS past 5Y1.74%
P/S9.22EPS next 5Y-3.48%
P/B1.47EPS Q/Q69.35%
Dividend-Sales Q/Q707.07%
Insider Own22.98%Inst Own89.79%
Insider Trans-14.54%Inst Trans-0.46%
Short Float28.12%EarningsMar 18/b
Analyst Recom1.20Target Price23.88
Avg Volume862.36K52W Range6.60 - 17.58
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDDirectorMar 18 '25Sale8.6710,38290,012148,253Mar 20 06:15 PM
Kaye Edward M. MDDirectorMar 19 '25Sale8.278,90773,661139,346Mar 20 06:15 PM
Ticho BarryCHIEF MEDICAL OFFICERMar 18 '25Sale8.673,88433,67463,962Mar 20 06:12 PM
Ticho BarryCHIEF MEDICAL OFFICERMar 19 '25Sale8.273,33327,56460,629Mar 20 06:12 PM
Allan JonathanGENERAL COUNSEL & CORP SECMar 18 '25Sale8.672,26619,64633,510Mar 20 06:05 PM
HOOK - Hookipa Pharma Inc - Stock Price Chart
TickerHOOK [NASD]
CompanyHookipa Pharma Inc
CountryUSA
IndustryBiotechnology
Market Cap12.42MEPS (ttm)-3.55
P/E-EPS this Y18.16%
Forward P/E-EPS next Y42.61%
PEG-EPS past 5Y32.13%
P/S0.28EPS next 5Y27.45%
P/B0.24EPS Q/Q17.48%
Dividend-Sales Q/Q-81.72%
Insider Own42.92%Inst Own24.08%
Insider Trans0.00%Inst Trans5.61%
Short Float1.03%EarningsFeb 28/b
Analyst Recom2.33Target Price4.50
Avg Volume119.29K52W Range1.06 - 105.00
HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.
CBAT - CBAK Energy Technology Inc - Stock Price Chart
TickerCBAT [NASD]
CompanyCBAK Energy Technology Inc
CountryChina
IndustryElectrical Equipment & Parts
Market Cap68.35MEPS (ttm)0.13
P/E5.81EPS this Y-69.23%
Forward P/E4.00EPS next Y375.00%
PEG-EPS past 5Y-
P/S0.39EPS next 5Y-
P/B0.56EPS Q/Q6.18%
Dividend-Sales Q/Q-54.84%
Insider Own20.43%Inst Own2.06%
Insider Trans0.00%Inst Trans-5.02%
Short Float1.37%EarningsMar 17/b
Analyst Recom-Target Price2.00
Avg Volume242.21K52W Range0.77 - 2.08
CBAK Energy Technology, Inc. engages in the manufacture, commercialization, and distribution of lithium-ion rechargeable batteries. Its products are used for electronic vehicles, light electric vehicles, electric tools, energy storage, uninterruptible power supply, and high-power applications. It operates through the CBAK and Hitrans segments. The CBAK segment mainly includes the manufacture, commercialization and distribution of a wide variety of standard and customized lithium-ion rechargeable batteries for use in a wide array of applications. The Hitrans segment covers the development and manufacturing of NCM precursor and cathode materials. The company was founded on October 4, 1999 and is headquartered in Dalian, China.
RCKT - Rocket Pharmaceuticals Inc - Stock Price Chart
TickerRCKT [NASD, RUT]
CompanyRocket Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap619.52MEPS (ttm)-2.73
P/E-EPS this Y10.43%
Forward P/E-EPS next Y34.78%
PEG-EPS past 5Y-11.60%
P/S-EPS next 5Y73.89%
P/B1.34EPS Q/Q3.22%
Dividend-Sales Q/Q-
Insider Own7.18%Inst Own101.06%
Insider Trans-0.86%Inst Trans24.01%
Short Float11.16%EarningsFeb 27/a
Analyst Recom1.12Target Price40.53
Avg Volume1.57M52W Range6.26 - 26.99
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwartz Jonathan DavidSee RemarksFeb 25 '25Sale10.586,53269,109237,638Feb 27 04:01 PM
Schwartz Jonathan DavidSee RemarksMay 17 '24Sale23.352,75464,306169,659Feb 27 04:01 PM
Schwartz Jonathan DavidSee RemarksAug 16 '24Sale18.502,71050,135166,949Feb 27 04:01 PM
Schwartz Jonathan DavidSee RemarksNov 21 '24Sale13.053,09740,416163,852Feb 27 04:01 PM
Patel KinnariSee RemarksFeb 21 '25Sale10.586,07864,305444,103Feb 25 04:01 PM
WPP - WPP Plc. ADR - Stock Price Chart
TickerWPP [NYSE]
CompanyWPP Plc. ADR
CountryUnited Kingdom
IndustryAdvertising Agencies
Market Cap7.81BEPS (ttm)3.20
P/E11.31EPS this Y-2.95%
Forward P/E6.55EPS next Y2.13%
PEG6.85EPS past 5Y-7.69%
P/S0.41EPS next 5Y1.65%
P/B1.80EPS Q/Q21779.57%
Dividend6.63%Sales Q/Q1.54%
Insider Own0.03%Inst Own8.87%
Insider Trans0.00%Inst Trans-52.27%
Short Float0.14%EarningsFeb 27/b
Analyst Recom3.13Target Price47.19
Avg Volume262.62K52W Range37.33 - 57.37
WPP Plc is a creative transformation company, which engages in the provision of communications services. It operates through the following segments: Global Integrated Agencies, Public Relations, and Specialist Agencies. The Global Integrated Agencies segment offers creative services including advertising, marketing, and brand strategies and campaigns across all media. The Public Relations segment helps clients communicate with all stakeholders, from consumers and investors to government and non-government organizations. The Specialist Agencies segment delivers brand experience and identity, and specialist, targeted services. The company was founded by Martin Stuart Sorrell in 1985 and is headquartered in London, the United Kingdom.
XNCR - Xencor Inc - Stock Price Chart
TickerXNCR [NASD, RUT]
CompanyXencor Inc
CountryUSA
IndustryBiotechnology
Market Cap682.78MEPS (ttm)-3.64
P/E-EPS this Y27.20%
Forward P/E-EPS next Y9.21%
PEG-EPS past 5Y-
P/S6.18EPS next 5Y19.57%
P/B1.00EPS Q/Q-45.17%
Dividend-Sales Q/Q3.58%
Insider Own6.14%Inst Own102.19%
Insider Trans-3.86%Inst Trans2.41%
Short Float9.18%EarningsFeb 27/b
Analyst Recom1.36Target Price30.30
Avg Volume626.15K52W Range10.40 - 27.24
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Valente NancyEVP, Chief Development OfficerMar 10 '25Sale13.602,56534,87753,785Mar 11 04:28 PM
Eckert CeliaSVP, GENERAL COUNSELMar 10 '25Sale13.605,74078,04763,507Mar 11 04:26 PM
Desjarlais John RSR. VICE PRESIDENT & CSOMar 10 '25Sale13.609,697131,851236,574Mar 11 04:25 PM
Dahiyat Bassil IPRESIDENT & CEOMar 10 '25Sale13.6019,716268,080465,419Mar 11 04:23 PM
Eckert CeliaOfficerMar 10 '25Proposed Sale13.605,74078,047Mar 10 04:26 PM
SPRB - Spruce Biosciences Inc - Stock Price Chart
TickerSPRB [NASD]
CompanySpruce Biosciences Inc
CountryUSA
IndustryBiotechnology
Market Cap11.08MEPS (ttm)-0.96
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-22.95%
P/S1.56EPS next 5Y-
P/B0.21EPS Q/Q30.84%
Dividend-Sales Q/Q-80.41%
Insider Own30.86%Inst Own23.54%
Insider Trans0.00%Inst Trans-8.16%
Short Float0.93%EarningsNov 11/b
Analyst Recom3.00Target Price1.50
Avg Volume363.94K52W Range0.28 - 0.87
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Charlton Ralph William IIICHIEF MEDICAL OFFICERDec 16 '24Option Exercise0.0058,3500172,668Dec 20 08:30 PM
Charlton Ralph William IIICHIEF MEDICAL OFFICERDec 10 '24Option Exercise0.00106,4000161,773Dec 20 08:30 PM
Gharib Samir M.PRESIDENT AND CFODec 16 '24Option Exercise0.0075,7500363,841Dec 20 08:28 PM
Gharib Samir M.PRESIDENT AND CFODec 10 '24Option Exercise0.00154,0000356,776Dec 20 08:28 PM
Szwarcberg Javier B.CHIEF EXECUTIVE OFFICERDec 16 '24Option Exercise0.00200,7000506,796Dec 20 08:28 PM
NTHI - NeOnc Technologies Holdings Inc - Stock Price Chart
TickerNTHI [NASD]
CompanyNeOnc Technologies Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap211.13MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own72.17%Inst Own-
Insider Trans0.00%Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume56.04K52W Range10.88 - 25.00
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Los Angeles, CA.
PYXS - Pyxis Oncology Inc - Stock Price Chart
TickerPYXS [NASD, RUT]
CompanyPyxis Oncology Inc
CountryUSA
IndustryBiotechnology
Market Cap56.35MEPS (ttm)-1.30
P/E-EPS this Y10.06%
Forward P/E-EPS next Y6.62%
PEG-EPS past 5Y-74.92%
P/S3.49EPS next 5Y1.32%
P/B0.45EPS Q/Q-71.31%
Dividend-Sales Q/Q-
Insider Own28.94%Inst Own39.30%
Insider Trans0.50%Inst Trans-27.12%
Short Float15.82%EarningsMar 18/b
Analyst Recom1.25Target Price7.50
Avg Volume605.16K52W Range0.98 - 6.18
Mar-25-25 04:30PM Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 (GlobeNewswire) -8.70%
Mar-18-25 07:30AM Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -8.62%
Mar-03-25 07:30AM Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -6.72%
Feb-26-25 07:30AM Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire) -5.83%
Feb-04-25 07:30AM Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial (GlobeNewswire)
Dec-21-24 07:40AM Pyxis Oncology price target lowered to $8 from $10 at RBC Capital (TipRanks)
Dec-19-24 04:08PM Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 (GlobeNewswire) +9.74%
Nov-20-24 04:05PM Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data (GlobeNewswire) -8.17% -45.03%
Nov-12-24 07:30AM Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 (GlobeNewswire)
Nov-11-24 07:00AM Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 (GlobeNewswire) +7.24%
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Connealy Pamela AnnCFO & COONov 26 '24Buy1.9688,850174,3641,199,143Nov 27 05:09 PM
CVM - Cel-Sci Corp - Stock Price Chart
TickerCVM [AMEX]
CompanyCel-Sci Corp
CountryUSA
IndustryBiotechnology
Market Cap18.46MEPS (ttm)-0.47
P/E-EPS this Y19.61%
Forward P/E-EPS next Y-
PEG-EPS past 5Y6.84%
P/S-EPS next 5Y-
P/B1.42EPS Q/Q21.75%
Dividend-Sales Q/Q-
Insider Own2.34%Inst Own8.22%
Insider Trans0.00%Inst Trans14.21%
Short Float5.75%EarningsFeb 18/b
Analyst Recom1.00Target Price10.00
Avg Volume1.36M52W Range0.22 - 2.39
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Watson Robert EugeneDirectorMay 08 '24Buy1.3920,00027,80024,431May 10 09:04 AM
PRICHEP PATRICIA BSenior Vice PresidentMay 08 '24Buy1.398,00011,120232,326May 09 01:07 PM
KERSTEN GEERT RChief Executive OfficerMay 08 '24Buy1.3930,00041,7001,195,309May 09 09:19 AM
1456789101112131420